Registration for a live webinar on 'Neuroleptic malignant syndrome' is now open.
See webinar detailsWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this free, full length talk
Topics Covered
- Vaccine development for SARS-COV-2: Current position
- Different types of potential vaccines against COVID-19
- New technologies and their implications
- How past experience can support current research
Biography
Gary Kobinger is a Professor in the Department of Microbiology and Infectious Diseases and the Director of the Research Centre on Infectious Diseases, Faculty of Medicine at Université Laval. He is also an adjunct Professor in the Department of Pathology and Laboratory Medicine at the University of Pennsylvania, and an Associate Professor in the Department of Medical Microbiology at the University of Manitoba.
His work focuses on developing and testing new vaccine platforms and immune treatments against emerging and re-emerging viruses of high consequences to public health.
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Kobinger, G. (2020, April 6). SARS-CoV-2 vaccine development: where are we now? [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved October 8, 2024, from https://doi.org/10.69645/LIUE8688.Export Citation (RIS)
Publication History
Financial Disclosures
- Consultant of Inovio Inc for their program on Lassa DNA vaccine development (not mentioned in the talk but the DNA platform for Zika is included and Inovio is on 2 of the slides to acknowledge their contribution). I have not received financial compensation yet however it is possible that I will this year or next to a maximum of $5000 USD/year.
Other Talks in the Playlist: Interviews on Covid-19
Transcript
Quiz
Disclaimer: This quiz is intended for learning assessment purposes only and does not grant any certification or credit.
If you are interested in getting a certificate for watching the talk, follow the instructions in this talk's Accreditation Information (where available.)